| Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients C Marzolini, A Telenti, LA Decosterd, G Greub, J Biollaz, T Buclin Aids 15 (1), 71-75, 2001 | 1116 | 2001 |
| Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients M Rotger, S Colombo, H Furrer, G Bleiber, T Buclin, BL Lee, O Keiser, ... Pharmacogenetics and genomics 15 (1), 1-5, 2005 | 482 | 2005 |
| Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection C Csajka, C Marzolini, K Fattinger, LA Décosterd, J Fellay, A Telenti, ... Clinical Pharmacology & Therapeutics 73 (1), 20-30, 2003 | 341 | 2003 |
| Diet acids and alkalis influence calcium retention in bone T Buclin, M Cosma, M Appenzeller, AF Jacquet, LA Decosterd, J Biollaz, ... Osteoporosis International 12, 493-499, 2001 | 313 | 2001 |
| Antihypertensive therapy with MK 4211: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade J Biollaz, HR Brunner, I Gavras, B Waeber, H Gavras Journal of cardiovascular pharmacology 4 (6), 966-972, 1982 | 310 | 1982 |
| Enalapril maleate and a lysine analogue (MK‐521): disposition in man. EH Ulm, M Hichens, HJ Gomez, AE Till, E Hand, TC Vassil, J Biollaz, ... British journal of clinical pharmacology 14 (3), 357-362, 1982 | 271 | 1982 |
| Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor" MK-421". H Gavras, B Waeber, I Gavras, J Biollaz, HR Brunner, RO Davies The Lancet 318 (8246), 543-547, 1981 | 235 | 1981 |
| Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist A Munafo, Y Christen, J Nussberger, LY Shum, RM Borland, RJ Lee, ... Clinical Pharmacology & Therapeutics 51 (5), 513-521, 1992 | 234 | 1992 |
| Renal drug transporters and drug interactions A Ivanyuk, F Livio, J Biollaz, T Buclin Clinical pharmacokinetics 56, 825-892, 2017 | 217 | 2017 |
| Population pharmacokinetics of imatinib and the role of α1‐acid glycoprotein N Widmer, LA Decosterd, C Csajka, S Leyvraz, MA Duchosal, A Rosselet, ... British journal of clinical pharmacology 62 (1), 97-112, 2006 | 216 | 2006 |
| Raised leptin concentrations at high altitude associated with loss of appetite M Tschöp, CJ Strasburger, G Hartmann, J Biollaz, P Bärtsch The Lancet 352 (9134), 1119-1120, 1998 | 193 | 1998 |
| Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. DB Brunner, G Desponds, J Biollaz, I Keller, F Ferber, H Gavras, ... British journal of clinical pharmacology 11 (5), 461-467, 1981 | 179 | 1981 |
| Three new long‐acting converting‐enzyme inhibitors: relationship between plasma converting‐enzyme activity and response to angiotensin I J Biollaz, M Burnier, GA Turini, DB Brunner, M Porchet, HJ Gomez, ... Clinical Pharmacology & Therapeutics 29 (5), 665-670, 1981 | 175 | 1981 |
| Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists C Csajka, T Buclin, HR Brunner, J Biollaz Clinical pharmacokinetics 32, 1-29, 1997 | 162 | 1997 |
| Pharmacogenetics‐based population pharmacokinetic analysis of efavirenz in HIV‐1‐infected individuals M Arab‐Alameddine, J Di Iulio, T Buclin, M Rotger, R Lubomirov, ... Clinical Pharmacology & Therapeutics 85 (5), 485-494, 2009 | 160 | 2009 |
| Effect of dronedarone on renal function in healthy subjects Y Tschuppert, T Buclin, LE Rothuizen, LA Decosterd, J Galleyrand, ... British journal of clinical pharmacology 64 (6), 785-791, 2007 | 156 | 2007 |
| Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor … C Marzolini, A Telenti, T Buclin, J Biollaz, LA Decosterd Journal of Chromatography B: Biomedical Sciences and Applications 740 (1), 43-58, 2000 | 154 | 2000 |
| Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations HR Brunner, J Menard, B Waeber, M Burnier, J Biollaz, J Nussberger Journal of hypertension 8 (1), 3, 1990 | 153 | 1990 |
| Transplacental passage of protease inhibitors at delivery C Marzolini, C Rudin, LA Decosterd, A Telenti, A Schreyer, J Biollaz, ... Aids 16 (6), 889-893, 2002 | 147 | 2002 |
| Enalapril maleate and a lysine analogue (MK‐521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. J Biollaz, JL Schelling, B Jacot des Combes, DB Brunner, G Desponds, ... British journal of clinical pharmacology 14 (3), 363-368, 1982 | 146 | 1982 |
Thierry BuclinCHUV and UNIL Lausanne (Switzewrland)Email verificata su chuv.hospvd.ch
